Cargando…
Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019
Remdesivir is a nucleotide analog prodrug with antiviral activity against a broad spectrum of human coronavirus in cell cultures and mouse models including severe acute respiratory syndrome–associated coronavirus 2. Recently, the Food and Drug Agency (FDA) and the European Medicines Agency (EMA) rec...
Autores principales: | Montastruc, François, Thuriot, Samuel, Durrieu, Geneviève |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the AGA Institute
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381904/ https://www.ncbi.nlm.nih.gov/pubmed/32721580 http://dx.doi.org/10.1016/j.cgh.2020.07.050 |
Ejemplares similares
-
Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns
por: Touafchia, Anthony, et al.
Publicado: (2021) -
Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective case–noncase study
por: Chouchana, Laurent, et al.
Publicado: (2021) -
Interactions between Medical Residents and Drug Companies: A National Survey after the Mediator® Affair
por: Montastruc, François, et al.
Publicado: (2014) -
Remdesivir and Mortality in Patients With Coronavirus Disease 2019
por: Diaz, George A, et al.
Publicado: (2021) -
Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study
por: Garcia, Philippe, et al.
Publicado: (2020)